International Journal of Hematology

, Volume 93, Issue 2, pp 257–259

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma

  • Shuji Ozaki
  • Takeshi Harada
  • Shiro Fujii
  • Shingen Nakamura
  • Hirokazu Miki
  • Ayako Nakano
  • Kumiko Kagawa
  • Kyoko Takeuchi
  • Masahiro Abe
  • Toshio Matsumoto
Letter to the Editor

References

  1. 1.
    International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.Google Scholar
  2. 2.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H, et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2010;92:118–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferrajoli A, Lee BN, Schlette EJ, O’Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94:1266–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007;12:252–65.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Shuji Ozaki
    • 1
    • 2
    • 3
  • Takeshi Harada
    • 1
    • 2
  • Shiro Fujii
    • 1
    • 2
  • Shingen Nakamura
    • 1
    • 2
  • Hirokazu Miki
    • 1
    • 2
  • Ayako Nakano
    • 1
    • 2
  • Kumiko Kagawa
    • 1
    • 2
  • Kyoko Takeuchi
    • 1
    • 2
  • Masahiro Abe
    • 1
    • 2
  • Toshio Matsumoto
    • 1
    • 3
  1. 1.Department of Medicine and Bioregulatory SciencesThe University of Tokushima Graduate School of Health BiosciencesTokushimaJapan
  2. 2.Department of HematologyTokushima University HospitalTokushimaJapan
  3. 3.Division of Transfusion MedicineTokushima University HospitalTokushimaJapan

Personalised recommendations